Tesamorelin (218949-48-5) video
Tesamorelin (218949-48-5) Description
Tesamorelin is a stabilized synthetic peptide analogue of the hypothalamic peptide, Growth Hormone Releasing Hormone (GHRH) indicated for the reduction of excess abdominal fat in HIV-infected patients with lipodystrophy. Lipodystrophy is a metabolic condition characterized by insulin resistance, fat redistribution, and hyperlipidemia associated with antiretroviral therapy for HIV infection.
Tesamorelin is used to reduce excess fat around the stomach that is caused by taking certain HIV medications. This condition is also called lipodystrophy (LYE-poe-DIS-troe-fee).
Tesamorelin (218949-48-5) Specifications
|Chemical Name||UNII-LGW5H38VE3; LGW5H38VE3; TH9507; Egrifta; Egrifta (TN)|
|Molecular Weight||5135.856 g/mol|
|Biological Half-Life||26 and 38 minutes in healthy subjects and HIV-infected patients, respectively.|
|Color||White lyophilized powder|
|Solubility||Soluble in water and very slightly soluble in methanol.|
|Storage Temperature||-20°C Freezer|
|Application||It can reduce excess fat (lipodystrophy) in the abdomen or stomach of HIV patients.|